<DOC>
	<DOCNO>NCT01457625</DOCNO>
	<brief_summary>Background Fetuin A , synthesized hepatocyte , circulatory inhibitor precipitation calcium phosphate link cardiovascular calcification mortality dialysis patient ; besides , associate insulin resistance general population . Hepatic fat accumulation enhance fetuin A secretion animal model . Objects This study design investigate association fetuin A level , insulin resistance hepatic fat content dialysis patient . Besides , plan observe survival dialysis patient different hepatic fat content . Methods . This prospective observational study . Three hundred fifty ESRD patient undergo maintenance HD PD recruit prospective investigation . All participant receive baseline abdominal ultrasound estimation hepatic fat content . Hepatic fat content estimate minimal , mild , moderate severe accord Hepburn classification . Besides , participant also check baseline fetuin A , HOMA-IR , hs-CRP , adiponectin , leptin lipid profile ( T-CHO , TG , LDL-C , HDL-C ) , nutritional parameter biochemical parameter . All participant follow 4 year survival analysis . The outcomes all-cause mortality composite CV mortality . Expected result Dialysis patient higher hepatic fat may higher fetuin A level may lead long-term survival benefit .</brief_summary>
	<brief_title>Clinical Study Serum Fetuin A Level , Insulin Resistance Hepatic Fat Content Dialysis Patients</brief_title>
	<detailed_description>Background : Fetuin A protein secrete hepatocytes inhibits insulin receptor tyrosine kinase adipose muscle cell ( 1 , 2 ) . Recently , inhibitory potency calcium phosphate precipitation link cardio-vascular ( CV ) calcification predict CV non-CV mortality dialysis patient ( 3 , 4 ) . In investigation , fetuin A deficiency associate high mortality , bad CV outcome dialysis patient . In recent study , fetuin A deficiency also link vascular access failure hemodialysis ( HD ) patient ( 5 ) . The pathogenesis bad survival fetuin A deficiency dialysis patient well-known . Nevertheless , association fetuin A deficiency progression vascular calcification atherosclerosis think possible mechanism high CV mortality ( 6 , 7 ) . In general population , fetuin A associated insulin resistance , metabolic syndrome obesity , , human high fetuin A concentration high insulin resistance ( 8 ) . Insulin resistance , diabetes metabolic syndrome important predictor long-term CV outcome general population ( 9 , 10 ) . In interventional study perform diabetic human normal kidney function , treatment pioglitazone seem decrease fetuin A level enhance insulin sensitivity ( 11 ) . In animal model , mice fatty liver present up-regulated fetuin A ( Ahsg ) mRNA expression ( 1 , 2 ) . In non-diabetic subject , fetuin A associate hepatic fat accumulation insulin resistance ( 12 ) . Moreover , recent investigation , fetuin A concentration associate body fat mass chronic kidney disease ( CKD ) patient yet receive dialysis ( 13 ) . In previous investigation , also find HD patient higher fetuin A concentration high risk truncal obesity hypertriglyceridemia ( 14 ) . These study suggest liver-secreted protein rapidly respond hepatic fat accumulation inhibits generation adiponectin adipose tissue ; therefore high fetuin-A low adiponectin may contribute obesity-induced insulin resistance development diabetes general population CKD patient ( 15 ) . However , relationship show dialysis patient . Although obesity , metabolic syndrome contribute high CV mortality general population ( 9 , 10 ) ; patient dialysis high BMI experience short-term survival benefit ( 16 ) . It so-called `` reverse epidemiology '' dialysis patient . Generally speak , well-nutrition dialysis patient experience less malnutrition-inflammation complex therefore , short-term survival benefit well-nutrition overcome long-term survival disadvantage bring over-nutrition obesity insulin resistance . However , ESRD patient abdominal obesity still high CV mortality risk ( 17 ) .The interesting part result investigation , fetuin A deficiency dialysis patient bad CV outcome ; contrary , high fetuin A level lead insulin resistance thereafter high CV mortality general population . It clear whether fetuin A concentration another `` reverse epidemiology '' dialysis patient . But dialysis patient well-nutrition , present high BMI , hepatic fat accumulation well survival . We hypothesize survival disadvantage fetuin A deficiency , frequently present dialysis patient , may major impact mortality short period time ; increase hepatic fat-accumulation ( over-nutrition ) may lead fetuin A secretion overwhelms short-term negative effect fetuin A deficiency survival , finally , lead protective effect high BMI , hepatic fat accumulation over-nutrition overall survival dialysis patient . Study purpose : This study design : 1 . To evaluate association hepatic fat content fetuin A concentration maintenance HD/PD patient 2 . To evaluate association fetuin A concentration insulin resistance marker HD/PD patient 3 . To evaluate overall survival ( 4-year ) HD/PD patient different content hepatic fat Study design method : This prospective observational study . Three hundred fifty ESRD patient undergo maintenance HD PD 6 month recruit prospective investigation . All participant receive baseline abdominal ultrasound estimation hepatic fat content . Hepatic fat content estimate minimal , mild , moderate severe accord Hepburn classification : absent ( affect 0 % 2 % hepatocytes ) , minimal ( 2 % 10 % ) , mild ( 10 % 30 % ) , moderate ( 30 % 60 % ) , severe ( 60 % hepatocytes ) . We choose abdominal ultrasound method hepatic fat estimation rather MRI CT gold standard hepatic fat estimation , limited use MRI dialysis patient increase cancer risk receive screen CT . Besides , participant also check baseline fetuin A , HOMA-IR , hs-CRP , adiponectin , leptin lipid profile ( T-CHO , TG , LDL-C , HDL-C ) , nutritional parameter biochemical parameter . All participant follow 4 year survival analysis . The outcomes all-cause mortality composite CV mortality .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<criteria>1 . ESRD patient undergoing maintenance HD PD 6 month 2 . Age &gt; 20 1 . Recent hospitalization duet active medical psychiatric problem 2 . Active malignancy 3 . Patient refusal</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>fetuin A liver fat content visceral obesity mortality</keyword>
</DOC>